Summary
Studies of the effect of sorbinil, an aldose reductase inhibitor, in human diabetic neuropathy have shown improvements in motor and sensory nerve conduction velocity and somatosensory evoked potentials, and a reduction in neuropathic pain. Improvements in motor and sensory deficits have also been detected clinically. These effects occurred after the administration of sorbinil for relatively short periods. However, more prolonged treatment may be necessary to achieve a therapeutic response in some patients. The results of tests of cardiac autonomic (vagal) function improved with the administration of sorbinil for 6 weeks. The most notable finding was a reduction in resting heart rate. Improvements in both clinical and test measures, related to autonomic and somatic nerve function, have reversed on withdrawal of sorbinil and improved again on renewal of administration. Toxic manifestations of sorbinil were infrequent, almost invariably mild, and readily reversible.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cogan DG, Kinoshita JH, Kador PF, Robison Jr WG, Datiles MB, et al. Aldose reductase and complications of diabetes. Annals of Internal Medicine 101: 82–91, 1984
Gillon KR, Hawthorne JN, Tomlinson DR. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition. Diabetologia 25: 365–371, 1983
Green DA, Lattimer SA. Action of sorbinil in diabetic peripheral nerve relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity. Diabetes 33: 712–716, 1984
Gupta PR, Dorfman LJ. Spinal somatosensory conduction in diabetes. Neurology 31: 841–845, 1981
Hosking DJ, Bennett T, Hampton JR. Diabetic autonomic neuropathy. Diabetes 27: 1043–1057, 1978
Jaspan JB, Maselli R, Herold K, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Lancet 2: 758–762, 1983
Jaspan JB, Herold K, Bartkus C. Effect of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. American Journal of Medicine 79 (Suppl. 5A): 24–37, 1985
Jaspan JB, Towle V, Maselli R, Herold KC. Clinical studies with an aldose reductase inhibitor in the autonomie and somatic neuropathies of diabetes. Metabolism 35 (Suppl. 1): 83–92, 1986
Judzewitch RG, Jaspan JB, Polonsky KS; Weinberg CR, Halter JB, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. New England Journal of Medicine 308: 119–125, 1983
Malone JC, Leavengood H, Peterson MJ, et al. Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin dependent diabetic subjects. Diabetes 33: 45–49, 1984
Young RJ, Ewing DJ, Clarke BF. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 32: 938–942, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jaspan, J. Pharmacological Inhibition of Aldose Reductase in Human Diabetic Neuropathy. Drugs 32 (Suppl 2), 23–29 (1986). https://doi.org/10.2165/00003495-198600322-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600322-00007